SCHEMBL4846415

SCHEMBL4846415

Nc1cc2cccoc-2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.54
MAP4K4 O95819 1/20 0.44
SMARCA2 P51531 1/20 0.43
PBRM1 Q86U86 1/20 0.43
ADORA2A P29274 3/20 0.43
KEAP1 Q14145 1/20 0.43
MAPT P10636 5/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
BLM P54132 3/20 0.41
PRMT6 Q96LA8 1/20 0.41
HSD17B10 Q99714 3/20 0.40
POLB P06746 3/20 0.40
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 2/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
KMT2A Q03164 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462178 0.83 TAAR1 (0.61) TAAR1MAP4K4SMARCA2PBRM1ADORA2A
SCHEMBL29433577 0.83 TAAR1 (0.61) TAAR1MAP4K4SMARCA2PBRM1ADORA2A
Hydrochloric Acid SCHEMBL1014896 0.81 TAAR1 (0.59) TAAR1MAP4K4SMARCA2PBRM1ADORA2A
SCHEMBL30417076 0.74 TAAR1 (0.55) TAAR1SMARCA2PBRM1ADORA2AMAPT
SCHEMBL27883785 0.73 PRMT6 (0.44) TAAR1ADORA2AKEAP1MAPTKDM4E
SCHEMBL28217068 0.72 TAAR1 (0.58) TAAR1SMARCA2PBRM1KEAP1MAPT
SCHEMBL1161258 0.70 TAAR1 (1.00) TAAR1ADORA2AMAPTKDM4EALDH1A1
SCHEMBL28874633 0.70 TAAR1 (0.66) TAAR1ADORA2AKEAP1MAPTKDM4E
Aniline SCHEMBL2657203 0.70 TAAR1 (0.73) TAAR1SMARCA2PBRM1ADORA2AKEAP1
SCHEMBL15519549 0.70 TAAR1 (0.61) TAAR1SMARCA2PBRM1ADORA2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442705-B2 HIV replication inhibiting pyrimidines and triazines TIBOTEC PHARMACEUTICALS LTD (IE) 2008-10-28 US disclosed
EP-1597238-B1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARM LTD (IE) 2007-05-09 EP disclosed
US-20060194804-A1 Hiv replication inhibiting pyrimidines and triazines TIBOTEC BVBA 2006-08-31 US disclosed
EP-1597238-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES Tibotec Pharmaceuticals Ltd. (IE) 2005-11-23 EP disclosed
WO-2004074262-A1 HIV REPLICATION INHIBITING PYRIMIDINES AND TRIAZINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194804-A1 Hiv replication inhibiting pyrimidines and triazines TYMS, UMPS, DUT TAAR1 3302/4885MAP4K4 2338/4885SMARCA2 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.